Should I Take Aspirin? (SITA): randomised controlled trial of a decision aid for cancer chemoprevention
British Journal of General Practice · 2024
DOI: 10.3399/bjgp.2023.0385 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of General Practice, 2024. Verfasst von Shakira R Onwuka und 16 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cancer Research, University of Melbourne; Department of General Practice and Primary Care, University of Melbourne; Melbourne School of Po…. Hauptthemen laut MEDLINE: Aspirin, Colorectal Neoplasms, Decision Support Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Australian guidelines recommend that people aged 50–70 years consider taking low-dose aspirin to reduce their risk of colorectal cancer (CRC).
Aim
To determine the effect of a consultation with a researcher before an appointment in general practice using a decision aid presenting the benefits and harms of taking low-dose aspirin compared with a general CRC prevention brochure on patients’ informed decision making and low-dose aspirin use. Design and setting Individually randomised controlled trial in six general practices in Victoria, Australia, from October 2020 to March 2021.
Method
Participants were recruited from a consecutive sample of patients aged 50–70 years attending a GP. The intervention was a consultation using a decision aid to discuss taking aspirin to reduce CRC risk while control consultations discussed reducing CRC risk generally. Self-reported co-primary outcomes were the proportion of individuals making informed choices about taking aspirin at 1 month and on low-dose aspirin uptake at 6 months, respectively. The intervention effect was estimated using a generalised linear model and reported with Bonferroni-adjusted 95% confidence intervals (CIs) and P -values.
Results
A total of 261 participants (86% of eligible patients) were randomised into trial arms ( n = 129 intervention; n = 132 control). Of these participants, 17.7% ( n = 20/113) in the intervention group and 7.6% ( n = 9/118) in the control group reported making an informed choice about taking aspirin at 1 month, an estimated 9.1% (95% CI = 0.29 to 18.5) between-arm difference in proportions (odds ratio [OR] 2.47, 97.5% CI = 0.94 to 6.52, P = 0.074). The proportions of individuals who reported taking aspirin at 6 months were 10.2% ( n = 12/118) of the intervention group versus 13.8% ( n = 16/116) of the control group, an estimated between-arm difference of −4.0% (95% CI = −13.5 to 5.5; OR 0.68 [97.5% CI = 0.27 to 1.70, P = 0.692]).
Conclusion
The decision aid improved informed decision making but this did not translate into long-term regular use of aspirin to reduce CRC risk. In future research, decision aids should be delivered alongside various implementation strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Cancer Research, University of Melbourne; Department of General Practice and Primary Care, University of Melbourne; Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Austra…
- Colorectal Medicine and Genetics, Royal Melbourne Hospital, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia.
- Department of General Practice and Primary Care, University of Melbourne, Melbourne, Australia.
- Centre for Cancer Research, University of Melbourne; Department of General Practice and Primary Care, University of Melbourne, Melbourne, Australia.
- Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Australia.
- National Health and Medical Research Council Professorial Fellow, cancer epidemiologist, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.
ORCID-Profile: Shakira R Onwuka, Jennifer McIntosh, Finlay Macrae, Patty Chondros, Lucy Boyd, Rushani Wijesuriya, Sibel Saya, Mark A Jenkins, Fiona M Walter, Lyndal Trevena, Javiera Martinez Gutierrez, Jon Emery
Zitieren
APA
Onwuka, S. R., McIntosh, J., Macrae, F., Chondros, P., Boyd, L., Wijesuriya, R., Saya, S., Karnchanachari, N., Novy, K., Jenkins, M. A., Walter, F. M., Trevena, L., Gutierrez, J. M., Broun, K., Fishman, G., Marker, J., & Emery, J. (2024). Should I Take Aspirin? (SITA): randomised controlled trial of a decision aid for cancer chemoprevention. British Journal of General Practice. https://doi.org/10.3399/bjgp.2023.0385
Vancouver
Onwuka SR, McIntosh J, Macrae F, Chondros P, Boyd L, Wijesuriya R, et al. Should I Take Aspirin? (SITA): randomised controlled trial of a decision aid for cancer chemoprevention. British Journal of General Practice. 2024. doi:10.3399/bjgp.2023.0385
BibTeX
@article{Onwuka2024,
author = {Onwuka, Shakira R and McIntosh, Jennifer and Macrae, Finlay and Chondros, Patty and Boyd, Lucy and Wijesuriya, Rushani and Saya, Sibel and Karnchanachari, Napin and Novy, Kitty and Jenkins, Mark A and Walter, Fiona M and Trevena, Lyndal and Gutierrez, Javiera Martinez and Broun, Kate and Fishman, George and Marker, Julie and Emery, Jon},
title = {Should I Take Aspirin? (SITA): randomised controlled trial of a decision aid for cancer chemoprevention},
journal = {British Journal of General Practice},
year = {2024},
doi = {10.3399/bjgp.2023.0385}
}
EUVIMED